Gross Profit Analysis: Comparing AstraZeneca PLC and Teva Pharmaceutical Industries Limited

AstraZeneca's profit soars, Teva faces challenges.

__timestampAstraZeneca PLCTeva Pharmaceutical Industries Limited
Wednesday, January 1, 20142025300000011056000000
Thursday, January 1, 20152006200000011356000000
Friday, January 1, 20161887600000011859000000
Sunday, January 1, 20171814700000010825000000
Monday, January 1, 2018171540000008296000000
Tuesday, January 1, 2019194630000007536000000
Wednesday, January 1, 2020213180000007725000000
Friday, January 1, 2021249800000007594000000
Saturday, January 1, 2022319600000006973000000
Sunday, January 1, 2023377710000007646000000
Monday, January 1, 2024438660000008064000000
Loading chart...

Unleashing the power of data

Gross Profit Trends: AstraZeneca vs. Teva

In the ever-evolving pharmaceutical industry, AstraZeneca PLC and Teva Pharmaceutical Industries Limited have showcased contrasting financial trajectories over the past decade. From 2014 to 2023, AstraZeneca's gross profit surged by approximately 86%, reflecting its strategic focus on innovative drug development and market expansion. In contrast, Teva's gross profit experienced a decline of around 31%, highlighting challenges in the generic drug market and competitive pressures.

AstraZeneca's growth is particularly notable from 2020 onwards, with a significant leap in 2022, marking a 50% increase compared to 2019. This period coincides with the company's successful rollout of new therapies and vaccines. Meanwhile, Teva's gross profit peaked in 2016 but has since faced a downward trend, underscoring the need for strategic realignment.

These insights provide a compelling narrative of resilience and adaptation in the pharmaceutical sector, offering valuable lessons for investors and industry stakeholders.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025